Journal
CHINESE CHEMICAL LETTERS
Volume 31, Issue 6, Pages 1427-1431Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cclet.2020.02.034
Keywords
Codelivery; Shielding; Doxorubicin; Bcl2 siRNA; Cancer therapy
Categories
Funding
- National Natural Science Foundation of China [51873208]
- National Science and Technology Major Projects for Major New Drugs Innovation and Development [2018ZX09711003-012]
- National Program for Support of Top-notch Young Professionals, Jilin Province Science and Technology Development Program [20180414027GH]
Ask authors/readers for more resources
A novel amphiphilic cationic block copolymer polylysine-b-polyphenylalanine (PLL-b-PPhe) was synthesized and self-assembled into micelles in aqueous solution, then shielded with poly(glutamic acid) (marked as PG/PLL-b-PPhe) to codeliver gene and drug for combination cancer therapy. Here, doxorubicin (DOX) was selected to be loaded into PLL-b-PPhe micelles and the drug loading efficiency was 8.0%. The drug release studies revealed that the PLL-b-PPhe micelles were pH sensitive and the released DOX could reach to 53.0%, 65.0%, 72.0% at pH 7.4, 6.8 and 5.0, respectively. In order to reduce positive charge and cytotoxicity of PLL-b-PPhe micelles, PG was used as shelding, simultaneously condensed with Bcl2 siRNA to form gene carrier system. Compared with PEI, PG/PLL-b-PPhe had excellent gene transfection efficiency, especially when the molar ratio of PLL to PPhe was 30:60 and the mixed mass ratio of PLL-b-PPhe to gene was 5:1. More importantly, DOX and Bcl2 siRNA gene codelivery system displayed remarkable cytotoxicity against B16F10 cells. Confocal laser scanning microscopy (CLSM) and flow cytometry were used to characterize endocytosis of the codelivery system, and confirmed that both DOX and Bcl2 siRNA had been endocytosed into B16F10 cells. The above results indicated that gene and drug codelivery was a promising strategy in future cancer therapy. (C) 2020 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available